URACIL MUSTARD
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Sep 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Uracil Mustard is an oral small-molecule alkylating agent approved in 1962 for hematologic malignancies. The drug operates through DNA cross-linking to induce cytotoxicity in rapidly dividing cells. It represents a legacy chemotherapy from the early era of cancer pharmacology.
LOE Approaching
Minimal active commercial team presence; product approaching loss of exclusivity with low competitive pressure (30), indicating limited growth investment or brand promotion activity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Uracil Mustard represents a legacy asset with zero linked job opportunities, indicating minimal active team development or expansion. Working on this product would primarily involve regulatory maintenance, compliance, or wind-down activities rather than strategic growth initiatives.
Regulatory Affairs SpecialistCompliance Officer
Worked on URACIL MUSTARD at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.